MENU
+Compare
MKGAF
Stock ticker: OTC
AS OF
Feb 3 closing price
Price
$142.33
Change
+$7.08 (+5.23%)
Capitalization
64.79B

MKGAF stock forecast, quote, news & analysis

Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare... Show more

MKGAF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for MKGAF with price predictions
Feb 02, 2026

MKGAF in downward trend: price may drop because broke its higher Bollinger Band on January 27, 2026

MKGAF broke above its upper Bollinger Band on January 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 43 similar instances where the stock broke above the upper band. In of the 43 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where MKGAF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on January 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MKGAF as a result. In of 123 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MKGAF turned negative on January 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MKGAF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MKGAF advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 252 cases where MKGAF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.813) is normal, around the industry mean (29.772). P/E Ratio (17.741) is within average values for comparable stocks, (74.035). Projected Growth (PEG Ratio) (2.578) is also within normal values, averaging (2.041). Dividend Yield (0.018) settles around the average of (0.029) among similar stocks. P/S Ratio (2.466) is also within normal values, averaging (112.501).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MKGAF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MKGAF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Dividends

MKGAF paid dividends on April 28, 2021

Merck KGaA MKGAF Stock Dividends
А dividend of $1.40 per share was paid with a record date of April 28, 2021, and an ex-dividend date of April 26, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.72B. The market cap for tickers in the group ranges from 2.12K to 64.79B. MKKGY holds the highest valuation in this group at 64.79B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 14%. CABR experienced the highest price growth at 27%, while SXTC experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 468%. For the same stocks of the Industry, the average monthly volume growth was 297% and the average quarterly volume growth was 175%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 57
SMR Rating: 80
Profit Risk Rating: 89
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
MKGAF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Frankfurter Strasse 250
Phone
+49 6151720
Employees
62908
Web
https://www.emdgroup.com